Mallinckrodt Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MALLINCKRODT INC, and when can generic versions of MALLINCKRODT INC drugs launch?
MALLINCKRODT INC has four approved drugs.
There are twelve US patents protecting MALLINCKRODT INC drugs.
There are thirty-one patent family members on MALLINCKRODT INC drugs in thirteen countries and sixty-seven supplementary protection certificates in eight countries.
Summary for Mallinckrodt Inc
International Patents: | 31 |
US Patents: | 12 |
Tradenames: | 4 |
Ingredients: | 4 |
NDAs: | 4 |
Drug Master File Entries: | 67 |
Drugs and US Patents for Mallinckrodt Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mallinckrodt Inc | XARTEMIS XR | acetaminophen; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 204031-001 | Mar 11, 2014 | DISCN | Yes | No | 9,050,335 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Mallinckrodt Inc | XARTEMIS XR | acetaminophen; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 204031-001 | Mar 11, 2014 | DISCN | Yes | No | 8,377,453 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Mallinckrodt Inc | XARTEMIS XR | acetaminophen; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 204031-001 | Mar 11, 2014 | DISCN | Yes | No | 7,976,870 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Mallinckrodt Inc | XARTEMIS XR | acetaminophen; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 204031-001 | Mar 11, 2014 | DISCN | Yes | No | 8,658,631 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Mallinckrodt Inc | XARTEMIS XR | acetaminophen; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 204031-001 | Mar 11, 2014 | DISCN | Yes | No | 9,468,636 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Mallinckrodt Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Mallinckrodt Inc | XARTEMIS XR | acetaminophen; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 204031-001 | Mar 11, 2014 | 6,488,962 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MALLINCKRODT INC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Extended-release Tablets | 7.5 mg/325 mg | ➤ Subscribe | 2014-04-03 |
Premature patent expirations for MALLINCKRODT INC
Expiration due to failure to pay maintenance fee
Patent Number | Expiration Date |
---|---|
⤷ Try a Trial | ⤷ Try a Trial |
International Patents for Mallinckrodt Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 5897036 | ⤷ Try a Trial |
Japan | 2014500315 | ⤷ Try a Trial |
Australia | 2009223061 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2009114648 | ⤷ Try a Trial |
Canada | 2720108 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Mallinckrodt Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0806968 | SPC/GB07/011 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003 |
1499331 | SPC/GB13/034 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313 |
2932970 | 18C1043 | France | ⤷ Try a Trial | PRODUCT NAME: UNE COMBINAISON COMPRENANT DU DOLUTEGRAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI,EN PARTICULIER LE SEL DE SODIUM DU DOLUTEGRAVIR,ET DE LA RILPIVIRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI,EN PARTICULIER LE CHLORHYDRATE DE RILPIVIRINE; REGISTRATION NO/DATE: EU/1/18/1282 20180518 |
2822954 | SPC/GB18/031 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM.; REGISTERED: UK EU/1/18/1289/001(NI) 20180625; UK EU/1/18/1289/002(NI) 20180625; UK PLGB 11972/0008 20180625 |
2932970 | SPC/GB18/041 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION COMPRISING DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. DOLUTEGRAVIR SODIUM) AND RILPIVIRINE OR A PHARAMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. RILPIVIRINE HYDROCHLORIDE); REGISTERED: UK EU/1/18/1282 20180518; UK PLGB 35728/0055 20180518; UK PLGB 35728/0056 20180518; UK PLGB 35728/0057 20180518 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.